This remarkable advancement was detailed in a recent publication in the journal Blood by a team from the Hubrecht Institute, Erasmus MC, and Sanquin. The study’s authors include prominent scientists Anna-Karina Felder, Sjoerd Tjalsma, Han Verhagen, and Rezin Majied, who indicate that the potential applications of this technique could extend beyond blood disorders. Instead of introducing foreign elements or new genes, the researchers utilized a strategy termed “delete-to-recruit,” a method that simply alters the proximity of genes and enhancers on the DNA strand. This creative approach paves the way for innovative treatments that exploit the body’s innate genetic architecture to address various diseases.

Gene activity is not a constant feature in cellular biology; many proteins, essential for bodily functions, are only necessary at specific times or under certain conditions. For example, some genes must be active during particular developmental windows or in response to environmental stimuli. Regulation of gene expression is thus crucial for maintaining cellular homeostasis. Enhancers serve as genetic switches that can activate genes located both nearby and far away in the genome, enabling a sophisticated mechanism of control over gene activation. This discovery lays the groundwork for a deeper understanding of gene regulation and its implications for various genetic disorders.

The central finding of this study reveals that by leveraging CRISPR-Cas9 technology, scientists can cut DNA segments that act as barriers between enhancers and their target genes. This effectively draws the enhancer closer, thereby facilitating the activation of genes that are typically dormant in adult cells—such as certain globin genes that are silent after birth but critical for proper hemoglobin function. This is particularly relevant for how the body handles oxygen transportation, a process that relies heavily on the production of functional hemoglobin.

For patients with sickle cell disease and beta-thalassemia, genetic mutations disrupt the function of adult globin genes, crucial for healthy red blood cell formation. This deficiency typically results in a variety of debilitating symptoms, including anemia, fatigue, and potential organ damage due to ineffective oxygen transport. The research team has demonstrated that their novel therapy has the potential to activate a backup system—the fetal globin gene—that could restore hemoglobin production. Although this gene is naturally inactive in adults, reactivating it could enable the production of functional hemoglobin, providing a vital alternative for symptomatic relief and possibly a path to a cure.

This technique has shown promise not only in laboratory settings but also in human experiments involving both healthy donors and patients suffering from sickle cell disease. The study’s success in blood stem cells is particularly important, as these cells are responsible for generating a wide array of blood cell types, including red blood cells. Reactivating the fetal globin gene in blood stem cells could provide a new source of healthy red blood cells, fundamentally changing treatment paradigms for genetic blood diseases characterized by a lack of functional adult globin proteins.

While the research remains in its infancy, it validates a new approach to gene therapies that could potentially overcome the limitations of current treatments. Traditional gene therapy methods often involve expensive and complex procedures that carry the risk of unintended genetic modifications. In contrast, the delete-to-recruit strategy presents a streamlined, more efficient alternative by focusing on enhancer-gene interactions without altering the genes themselves. This transformative method encourages a nuanced understanding of gene regulation and has vast implications for a range of genetic conditions.

Moreover, the researchers believe that the implications of their findings could reach far beyond blood disorders. The ability to reactivate dormant genes may apply to various other genetic diseases where the low expression of healthy proteins can be remedied by turning on backup gene systems. As the scientific community continues to unlock the intricacies of gene regulation, it becomes possible to consider treatment possibilities for a diverse array of ailments, potentially democratizing access to effective therapies.

Though current gene therapies like those that received approval for use in Europe in 2024 have shown benefits, they also present significant drawbacks, particularly concerning accessibility and affordability. The therapies modify genes critical for hemoglobin production and can inadvertently activate other genetic pathways with unknown effects. In contrast, the new delete-to-recruit method enhances existing genetic frameworks while minimizing risks associated with traditional gene editing techniques.

As this research progresses, it sets the stage for future clinical applications that can provide effective therapies for genetic blood disorders. The prospect of reactivating and revitalizing dormant genes fundamentally alters the landscape of gene therapy as it currently exists. This development holds promise for better health outcomes and improved quality of life for those afflicted with conditions that have long posed considerable therapeutic challenges.

In summary, this extraordinary study not only opens new avenues for treating genetic blood diseases but also signals a paradigm shift in how we think about gene therapy and genetic regulation. The innovative delete-to-recruit method exemplifies a new approach that could simplify and enhance treatment options for a variety of genetic disorders, perhaps leading us closer to more widespread and accessible gene therapies in the future. The implications of this research could substantially reshape our understanding of genetics and its application in clinical settings, heralding an exciting era of possibilities in medical science.

Subject of Research: Cells
Article Title: Reactivation of developmentally silenced globin genes through forced linear recruitment of remote enhancers
News Publication Date: 2025
Web References: N/A
References: N/A
Image Credits: Annelie Martens

Keywords

Gene therapy, Sickle cell anemia, Thalassemia, Hemoglobin, CRISPR, Erythrocytes

Historically, gene therapy using lentiviral vectors has demonstrated notable successes when performed ex vivo, where a patient’s stem cells are extracted, modified in a laboratory setting, and then reinfused after undergoing chemotherapy. One prominent example of this application is the therapy for metachromatic leukodystrophy (MLD), developed at SR-Tiget and approved in Europe and the United States. However, while this methodology has proven effective, it is also resource-intensive and presents challenges regarding patient comfort and treatment accessibility.

The innovative approach detailed in the recent study diverges from traditional practices by administering lentiviral vectors directly into the bloodstream in vivo. This method takes advantage of the unique physiological circumstances present in newborn mice. It was observed that during the first two weeks of life, the numbers of hematopoietic stem and progenitor cells (HSPCs) circulating in the bloodstream significantly surpass those found in older animals. This elevated presence of stem cells provides a critical window for gene transfer through systemic injection, facilitating long-term engraftment and the production of multilineage blood cells.

Dr. Michela Milani, the study’s lead author, articulated the significance of these findings by emphasizing the journey of blood stem cells post-birth. According to her, after birth, these stem cells must migrate from the liver—where they reside during the latter stages of pregnancy—to their permanent location in the bone marrow. This journey through the bloodstream creates an unparalleled opportunity for intravenous delivery of gene-modifying vectors, allowing for genetic alterations without the need for prior harvesting or lab processing of the cells.

To substantiate their research further, the team tested their novel in vivo gene transfer approach in mouse models simulating three distinct genetic disorders: adenine deaminase-deficient severe combined immunodeficiency (ADA-SCID), autosomal recessive osteopetrosis, and Fanconi anemia. In all three scenarios, the application of gene transfer was found to yield considerable therapeutic benefits. Notably, in the model pertaining to Fanconi anemia, corrected stem cells were able to progressively repopulate the blood system, thus averting the onset of bone marrow failure. This outcome closely mirrors what has been observed in human gene therapy studies wherein corrected cells demonstrate a survival and growth advantage over defective counterparts.

The researchers also aimed to enhance the effectiveness of gene transfer by utilizing clinically approved mobilizing agents such as G-CSF and Plerixafor. These substances were employed to dislodge stem cells from their tissue niches, ultimately resulting in an increased population of circulating stem cells and extending the potential treatment window to include older mice. Furthermore, the team optimized the lentiviral vectors to bolster their stability and improve cellular uptake—contributing to greater gene transfer efficiencies.

Significantly, the researchers detected HSPCs circulating in the blood of human newborns during the early months of life, which aligns with their earlier observations in mouse models. This finding reinforces the prospect that a similar opportunity for gene therapy may broadly exist in human populations. Dr. Alessio Cantore, another prominent figure in the study, remarked on the implications of their findings, suggesting that they provide proof of principle that in vivo lentiviral gene delivery is feasible during a crucial early-life window. If confirmed in human neonates, this method could have substantial implications for treating genetic diseases like severe immunodeficiencies and Fanconi anemia.

Moreover, the researchers noted an intriguing contrast in the behavior of stem cells between young and adult organisms. When stem cells are harvested from the blood of adult mice or humans, even with the aid of mobilizing drugs, they typically require additional activation signals to facilitate effective lentiviral gene transfer. Conversely, at the newborn stage, not only is there a greater abundance of circulating stem cells, but those cells also exhibit a higher degree of responsiveness to gene transfer efforts. This biological distinction underscores the necessity for further investigations into the mechanisms that govern this increased permissiveness in younger organisms, with aspirations to translate these findings to older age groups.

In conclusion, the research conducted by the SR-Tiget team illuminates a potentially transformative paradigm in the treatment of genetic blood disorders. By harnessing the properties of blood stem cells during a critical developmental window, they have opened a new avenue for therapeutic intervention that could refine and elevate the standard of care for patients burdened by genetic abnormalities. The implications of these findings not only underscore the importance of timing in medical treatments but also mark a pivotal advancement in the burgeoning field of gene therapy.

Subject of Research: Gene therapy targeting hematopoietic stem cells
Article Title: In Vivo Hemopoietic Stem Cell Gene Therapy Enabled by Post-Natal Trafficking
News Publication Date: 28-May-2025
Web References: Nature
References: 10.1038/s41586-025-09070-3
Image Credits: Ella Maru Studio

Keywords

Gene therapy, hematopoietic stem cells, lentiviral vectors, ex vivo, in vivo, genetic disorders, neonatal blood circulation, SR-Tiget, Milan, bone marrow failure, adenine deaminase-deficient severe combined immunodeficiency (ADA-SCID), gene transfer efficiency.